Cesca Therapeutics to Present at the Inaugural Cell and Gene Exchange 2017

RANCHO CORDOVA, Calif., May 18, 2017 -- Cesca Therapeutics Inc. (NASDAQ:KOOL), a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced that Dr. Dalip Sethi, senior director of research and development, will be presenting at the Cell and Gene Exchange 2017, taking place May 22-23 at the Ronald Reagan Building in Washington, DC. Dr. Sethi will present at 2:45pm EDT on Tuesday, May 23, 2017.

“As a leading developer of automated technologies for cell-based therapeutics, we are delighted to take part in the inaugural Cell and Gene Exchange partnering conference, and look forward to presenting an overview of our broad capabilities in this rapidly-growing field,” said Dr. Sethi. “Cell-based therapies are at the foundation of many of today’s most exciting clinical advancements. Our cutting-edge technology, which is built on our flagship AutoXpress® processing platform, together with our proprietary therapeutic development programs, have helped make Cesca Therapeutics the partner of choice for many of the leading medical institutions in the world.”

About the Inaugural Cell and Gene Exchange
The Cell and Gene Exchange is a leading partnering forum focused on the regulatory, business, and patient advocate communities in cell and gene therapy sectors.

About Cesca Therapeutics Inc.
Cesca is a leading regenerative medicine company that develops, commercializes and markets a range of automated technologies for cell-based therapeutics. Its device division, ThermoGenesis, provides a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology.  Cesca is also leveraging its proprietary AutoXpress® technology platform to develop autologous stem cell-based therapies that address significant unmet needs in the vascular, cardiology and orthopedic markets.

Cesca is an affiliate of the BoyaLife Group, a China-based industry research alliance encompassing top research institutions for stem cell and regenerative medicine.

Forward-Looking Statement

The statements contained herein may include statements of future expectations and other forward-looking statements that are based on management’s current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. A more complete description of risks that could cause actual events to differ from the outcomes predicted by Cesca Therapeutics' forward-looking statements is set forth under the caption "Risk Factors" in Cesca Therapeutics’ annual report on Form 10-K and other reports it files with the Securities and Exchange Commission from time to time, and you should consider each of those factors when evaluating the forward-looking statements.

Company Contact: Cesca Therapeutics Inc. 
[email protected]

Investor Contact: 
Rx Communications
Paula Schwartz
917-322-2216
[email protected]